pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

NIH Scales Back Replication Initiative, Critics Warn It Undermines Scientific Rigor

Oct 21, 2026·read at STAT ↗Negative

NIH originally announced a push to make replication a core part of biomedical research, including an $850,000 Replication Prize launched in March 2025.

Health secretary Robert F. Kennedy Jr. suggested dedicating roughly 20% of the agency’s $47 billion budget to replication, but the NIH Council of Councils flagged the plan as potentially too costly and as possibly eroding confidence in individual scientists.

In response, the agency trimmed the program to $174 million, framing the reduced budget as support for rigorous methods and routine replication rather than a large‑scale prize effort.

The author, Mark Louie F. Ramos, argues that cost concerns do not outweigh the need for systematic replication, insisting that continued investment is the best way to ensure reliable science.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Replication is necessary even if scientists do everything right”

read at STAT ↗
1,053 words · retrieved 49m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AMICUS THERAPEUTICS, INC.National Institutes of HealthPATH

related stories

  • 20h agoEyepoint, Enlivex enact heavy layoffsBioSpace
  • 1d agoAlnylam bulls and bears fight it out after business-shaking guidance cutBioSpace
  • 4d agoiPSCs come of age, powering breakthroughs in the lab and clinicBioSpace
  • Oct 2NIH rolling out streamlined website to help public find information more easilySTAT
  • Sep 23Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace